Burning Rock Biotech focuses on providing individualized cancer treatment guidance for the patients.
Burning Rock focuses on providing individualized cancer treatment guidance for the patients. Using medical and bio informatics plus Next-Generation Sequencing (NGS) as the core technologies, the company is committed to offering one-stop solution for clinical and R&D services concerning the genetic testing of individualized cancer treatment.Established in March 2014, Burning Rock is headquartered in Beijing. Its first medical laboratory, "Guangzhou Burning Rock Medical Examination Institute Co., Ltd." is situated on Guangzhou International Bio Island which is blessed with a picturesque environment and rich in scientific research deposits. Later it established a R&D center in Shanghai. It occupies over 10,000 ㎡ in total. Burning Rock is committed to guiding the individualistic treatment of tumor patients, centered around NGS and biomedical informatics, with conventional tumor molecular pathology detection as the cornerstone, trying to build one-stop solutions for individualistic treatment clinical detection service and scientific research of tumor.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 14, 2019 | Series C | ¥850M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Lilly Asia Ventures | — | Series C |